USRE39496E1 - Kahalalide F and compositions and uses thereof - Google Patents

Kahalalide F and compositions and uses thereof Download PDF

Info

Publication number
USRE39496E1
USRE39496E1 US10/642,006 US64200603A USRE39496E US RE39496 E1 USRE39496 E1 US RE39496E1 US 64200603 A US64200603 A US 64200603A US RE39496 E USRE39496 E US RE39496E
Authority
US
United States
Prior art keywords
val
compound
thr
ileu
mehex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/642,006
Inventor
Mark T. Hamann
Dolores G. Gravalos
Paul J. Scheuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939302046A external-priority patent/GB9302046D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Priority to US10/642,006 priority Critical patent/USRE39496E1/en
Application granted granted Critical
Publication of USRE39496E1 publication Critical patent/USRE39496E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention is concerned with a cytotoxic and antiviral compound isolated from the sacoglossan, Elysia rafescens rufescens.
  • the present invention also provides a method of treating any mammal affected by a malignant tumor sensitive to compounds above described, which comprises administering to the affected individual a therapeutically effective amount of these compounds or a pharmaceutical composition thereof; and a method of treating viral infections in mammals, comprising administering to a patient in need of such treatment, an antiviral effective amount of the compounds described in the present invention.
  • the present invention also relates to pharmaceutical preparations which contain as active ingredient these compounds, or a pharmaceutically acceptable acid addition salt thereof, as well as the process for its preparation.
  • compositions include any solid (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) suitable composition for oral, topical or parenteral administration, and they may contain the pure compound or in combination with any carrier or other pharmacologically active compounds. These compositions may need to be sterile when administered parenterally.
  • a pharmaceutical composition of these compounds this compound will vary according to the particular formulation, the mode of application and particular site, host and tumor being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of disease shall be taken in account. Administration can be carried out continuously or periodically within the maximum tolerated dose.
  • Kahalalide F was isolated from the sacoglossan, Elysia rufescens Elysia rufescens (family Plakobranchidae, order Sacoglossa), collected near Black point Point, Oahu. This animal varies in size between 1 and 4 cm; it is dark red-brown in color with light-colored spots. There is orange fringing of the parapodia, which have very small dark green spots from sequestered chloroplasts. Elysia rufescens feeds on the delicate, feather-like green alga Bryopsis Bryopsis sp. 1 Kahalalide F can also be isolated from this alga.
  • Kahalalide F was isolated as a white amorphous powder in 0.02% 0 . 01 % yield.
  • a molecular formula of C 75 H 124 N 14 O 16 was deduced from detailed analyses of the 13 C and 1 H NMR spectra and the high resolution FAB mass spectrum.
  • the 14 substructures in this compound arise from five valines, two isoleucines, two threonines, ornithine, dehydroaminobutyric acid. , proline, phenilalanine phenylalanine and 5-methythexanoic 5 - methylhexanoic acid (5-MeHex).
  • Kahalalide F is the largest peptide in this series of compounds.
  • Optical rotations were measured on a Jasco DIP-370 digital polarimeter. Infrared spectra were recorded on a Nicolet MX-5 FTIR spectrometer. Gas chromatography was accomplished using a Hewlett-Packard Model 5890 instrument. Mass spectra were measured on a VG-70SE magnetic sector mass spectrometer. NMR spectra were measured on a General Electric QE-300 or a GN OMEGA 500 instrument. 1 H NMR chemical shifts are reported in ppm with the chemical shift of the residual protons of the solvent used as internal standards. 13 C NMR chemical shifts are reported in ppm by using the natural abundance 13 C of the solvent as an internal standard. Ultraviolet spectra were recorded on a Hewlett-Packard Model 8452A diode array spectrophotometer. All solvents were distilled from glass before use.
  • Kahalalide F consists of 2-D-allo-Ileu, L-Orn, L-Phe, D-Pro, L-Thr, D-Allo-Thr, 3 D-Val and 2 L-Val.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

KalahideKahalalide F, of formula I below, may be isolated from a sacoglossan. The compound may be used in the manufacture of pharmaceutical compositions or in the treatment of tumors or viral conditions
Figure USRE039496-20070227-C00001

Description

This invention is concerned with a cytotoxic and antiviral compound isolated from the sacoglossan, Elysia rafescens rufescens.
According to the invention there is provided, a the new compound, the peptide, Kahalalide F, of the formula I:
Figure USRE039496-20070227-C00002
The antitumor activities of this compound has been determined “in vitro” in cell cultures of human lung carcinoma A-549 and human colon carcinoma HT-29. The procedure was carried out using the metnhodology methodology described by Raymond J. Bergeron et al. Biochem. Bioph. Res. Comm. 1984, 121(3), 848-854 and by Alan C. Schroeder et al. J. Med. Chem. 1981, 24 1078-1083.
The antiviral activities of this compound the compound Kahalalide F have also been determined “in vitro” against HSV (Herpes simplex virus) and VSV (Vesicular stomatitis virus). The methodology used to carry out this determination is described by Raymond J. Bergeron et al. Biochem. Bioph. Res. Comm. 1984, 121(3), 848-854 and by Alan C. Schroeder et al. J. Med. Chem. 1981, 24 1078-1083.
Therefore, the present invention also provides a method of treating any mammal affected by a malignant tumor sensitive to compounds above described, which comprises administering to the affected individual a therapeutically effective amount of these compounds or a pharmaceutical composition thereof; and a method of treating viral infections in mammals, comprising administering to a patient in need of such treatment, an antiviral effective amount of the compounds described in the present invention.
The present invention also relates to pharmaceutical preparations which contain as active ingredient these compounds, or a pharmaceutically acceptable acid addition salt thereof, as well as the process for its preparation.
Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) suitable composition for oral, topical or parenteral administration, and they may contain the pure compound or in combination with any carrier or other pharmacologically active compounds. These compositions may need to be sterile when administered parenterally.
The correct dosage of a pharmaceutical composition of these compounds this compound will vary according to the particular formulation, the mode of application and particular site, host and tumor being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of disease shall be taken in account. Administration can be carried out continuously or periodically within the maximum tolerated dose.
Kahalalide F was isolated from the sacoglossan, Elysia rufescens Elysia rufescens (family Plakobranchidae, order Sacoglossa), collected near Black point Point, Oahu. This animal varies in size between 1 and 4 cm; it is dark red-brown in color with light-colored spots. There is orange fringing of the parapodia, which have very small dark green spots from sequestered chloroplasts. Elysia rufescens feeds on the delicate, feather-like green alga Bryopsis Bryopsis sp. 1 Kahalalide F can also be isolated from this alga. Two hundred animals were collected over the period of several weeks during the spring, of 1991 and extracted with EtOH. The extracts were then chromatographed by silica gel flash chromatography (hexane, hexane/EtOAc (1:1), EtOAc, EtOAc (1:1) EtOAc/MeOH ( 1:1 ), MeOH and MeOH/HOAc (98:2)). The peptides were eluted with EtOAc/MeOH (1:1). Final purification was accomplished by repeated HPLC (RP C18) using MeCN/H2O with 0.1% TFA (70-45% H2O).
Figure USRE039496-20070227-C00003
The structures of the peptides were elucidated by 2D NMR experiments (HMQC, HMBC, TOCSY, COSY and ROESY).
Kahalalide F was isolated as a white amorphous powder in 0.02% 0.01% yield. A molecular formula of C75H124N14O16 was deduced from detailed analyses of the 13C and 1H NMR spectra and the high resolution FAB mass spectrum. The 14 substructures in this compound arise from five valines, two isoleucines, two threonines, ornithine, dehydroaminobutyric acid. , proline, phenilalanine phenylalanine and 5-methythexanoic 5-methylhexanoic acid (5-MeHex). Kahalalide F is the largest peptide in this series of compounds.
EXPERIMENTAL
General Considerations
Optical rotations were measured on a Jasco DIP-370 digital polarimeter. Infrared spectra were recorded on a Nicolet MX-5 FTIR spectrometer. Gas chromatography was accomplished using a Hewlett-Packard Model 5890 instrument. Mass spectra were measured on a VG-70SE magnetic sector mass spectrometer. NMR spectra were measured on a General Electric QE-300 or a GN OMEGA 500 instrument. 1H NMR chemical shifts are reported in ppm with the chemical shift of the residual protons of the solvent used as internal standards. 13C NMR chemical shifts are reported in ppm by using the natural abundance 13C of the solvent as an internal standard. Ultraviolet spectra were recorded on a Hewlett-Packard Model 8452A diode array spectrophotometer. All solvents were distilled from glass before use.
Two hundred sacoglossans (Elysia rufescens), were collected at Black Point, O'ahu during April and May 1992 1991, and extracted 3 times with EtOH. Spring appears to be the time of year Elysia rufescens is in greatest abundance at Black Point. The combined extracts were then chromatographed using silica gel flash chromatography (hexane, hexane/EtOAc (1:1), EtOAc, EtOAc/MeOH (1:1), MeOH, MeOH/HOAc (98:2)). The depsipeptides were found in the EtOAc/MeOH (1:1) fraction. Repeated HPLC RP18 RP C18 MeCN/H2O/TFA (55/45/1 30/70/1)—MeCN/H2O/TFA ((30/70/1 55/45/1) yielded six the new depsipeptides.
KAHALALDDE FKAHALALIDE F
Final purification was accomplished by HPLC on RP18 RP C18 MeCN/H2O/TFA (55/45/1). Physical data: [α]D-8° [α]D- 8° (c 4.32, MeOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, m); Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ileu-1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz); Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 ( 3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85, (NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation) d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5-MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=7.2 Hz); 5-MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m), 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m) ; 13C NMR (125 MHz TFA/DMF): amino acid unit, δ (carbon position); Val-1 70.40 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 12.68 (4); Phe 171.31 (1), 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172-94 172.94 (1), 58.57 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4), 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5), 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7) ; IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1465 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85) (calcd for C75H125N14O16: 1477.9398); UV (MeOH): λmax 204 (89,630) nm.
Amino acid analysis by GC-MS with a Chirasil-Val column indicates that Kahalalide F consists of 2-D-allo-Ileu, L-Orn, L-Phe, D-Pro, L-Thr, D-Allo-Thr, 3 D-Val and 2 L-Val.
TABLE IITABLE I
1H and 13C NMR Data for Kahalalide F (I)KF in DMF/TFA
Amino Acid Carbon 13C, ppma Mult. 1H, ppmb Multiplicity
Valine-1 1 170.4 s (NH) 7.11 d, J=8.9
2 60.3 d 4.16 t, J=9.0
3 30.8 d 1.77 m
4 19.6 q 0.95 m
5 18.8 q 0.95 m
Dehydroamino 1 164.5 s (NH) 9.20 s
butyric acid 2 130.3 s
3 131.3 d 6.48 q, J=6.9
4 12.7 q 1.43 d, J=6.6
Phenylalanine 1 171.3 s (NH) 8.62 d, J=6.6
2 56.3 d 4.68 q, J=6.6
3 36.8 t 3.23 dd, J=13.7,
3.00 7.2
3.00 dd, J=13.7,
9.0
4 138.2 s
5, 5′ 129.9 d 7.32 d, J=7.2
6, 6′ 128.8 d 7.28 t, J=7.5
7 127.0 d 7.21 t, J=7.2
Valine-2 1 172.9 s (NH) 7.82 d, J=6.6
2 58.6 d 4.36 m
3 32.4 d 2.12 m
4 18.0 q 0.85 m
5 17.6 q 0.77 d, J=6.6
Isoleucine-1 1 171.9 s (NH) 8.38 d, J=0.6
2 57.5 d 4.53 m
3 38.8 d 1.98 m
4 14.6 q 0.92 d, J=6.6
5 26.8 t 1.40, 1.13 m, m
6 11.7 q 0.88 t, J=7.2
Threonine-1 1 169.7 s (NH) 8.12 d, J=5.7
2 57.4 d 4.63 t, J=9.3
3 71.1 d 5.07 dq, J=9.6, 6.0
4 17.3 q 1.18 d, J=6.3
Isoleucine-2 1 171.9 s (NH) 7.72 d, J=8.4
2 57.3 d 4.52 m
3 38.0 d 1.88 m
4 14.8 q 0.88 d, J=6.3
5 26.6 t 1.40, 1.13 m, m
6 11.6 q 0.88 t, J=7.2
Ornithine 1 172.0 s (NH) 7.92 d, J=7.8
2 52.9 d 4.48 m
3 29.6 t 1.76 m
4 24.4 t 1.83 m
5 40.1 t 3.10 p, 5.1
Proline 1 172.6 s
2 60.2 d 4.42 m
3 29.6 t 2.12, 1.97 m, m
4 25.4 t 2.02, 1.88 m, m
5 48.0 t 3.75, 3.68 m, m
Valine-3 1 171.3 s (NH) 7.90 d, J=7.2
2 57.6 d 4.41 m
3 30.5 d 2.12 m
4 19.6 q 0.95 m
5 18.8 q 0.85 m
Valine-4 1 171.8 s (NH) 7.68 d, J=8.1
2 59.1 d 4.34 m
3 31.3 d 2.17 m
4 19.5 q 0.95 m
5 18.1 q 0.90 m
Threonine-2 1 171.0 s (NH) 7.77 d, J=8.1
2 58.9 d 4.46 m
3 67.4 d 4.21 dq, J=6.3, 3.6
4 19.7 q 1.12 d, J=6.6
Valine-5 1 172.7 s (NH) 7.85 d, J=8.1
conf. #2 7.85 d, J=7.81
(NH) 7.82
2 59.6 d 4.32 m
3 30.7 d 2.14 m
4 19.6 q 0.95 m
5 18.4 q 0.90 m
5-Methyl- 1 173.8 s
Hexanoic acid 2 36.3 t 2.26 m
3 24.0 t 1.60 m
4 39.0 t 1.20 m
5 28.1 d 1.55 m
6 22.5 q 0.87 d, J=7.2
7 22.5 q 0.87 d, J=7.2
5-Methyl- 1 174.1 s
Hexanoic acid 2 33.9 t 2.29 m
(second 3 32.8 t 1.65, 1.40 m
conformation) 4 29.8 t 1.13 m
5 34.5 d 1.35 m
6 19.5 q 0.90 m
7 11.2 q 0.90 m
aat 125 MHz, DMF signal at 35.2 ppm;
bat 500 MHz, DMF signal at 2.91 ppm.
TABLE ITABLE II
In vitro Activity of Kahalalide F KF from Elysia rufescens
Assay (M.I.C. μg/mL)
Cytoxicity μg/mL (IC50)
A-549 2.5
HT-29 0.25-0.5
Antiviral μg/mL (% reduction)
Mv 2 Lu/HSV II 0.5 (95%)
CV-1/HSV-1 >8
BHK/VSV >8
Antifungal 6 mm disk 50 μg/disk
Aspergillus oryzae 19 mm
Penicillium notatum 26 mm
Tricophyton mentagrophy 34 mm
Saccharomyces cerevisiac neg
Candida albicans 16 mm

Claims (10)

1. A substially Substantially pure compound Kahalalide F compound, said compound hag having a molecular formula of C75H124N14O16, and consisting of five valines, two isoleucines, two threonines, ornithine, dehydroaminobutynic dehydroaminobutyric acid, proline, phenylalanine and 5-methylhexanoic acid; said compound further exhibiting the following physical and chemical properties: [α]D-8° (c 4.32, MeOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8,9 8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, m), Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Vol-2 Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ileu-1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (HN NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz) Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 (3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1 Hz), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85 (HN NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation), d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5-MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=72 7.2 Hz); 5-MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m), 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m); 13C NMR (125 MHz TFA/DMF): amino acid unit, δ (carbon position); Val-1 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 126.6 12.68 (4); Phe 171.31 (1), 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172.94 (1), 58.57 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4) 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); thr-2 Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5); 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7); IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1464 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85); UV (MeOH): λmax 204 (89,630) nm.
2. The compound Kahalalide F compound of claim 1, which further has the folowing following non-stereospecific structure:
Figure USRE039496-20070227-C00004
3. A pharmaceutical compostion composition comprising a pharmaceutical carrier or diluent and the substantially pure compound Kahalalide F, said compoumd compound having a molecular formula of C75H124N14O16, and conng consisting of five valines, two isoleucines, two threonines, ornithine, dehydroamiobutyric dehydroaminobutyric acid, proline, phenylalanine and 5-methylhexoic 5-methylhexanoic acid; said compound further exhibiting the following physical and chemical properties:
[α]D-8° (c 4.32, MEOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8,9 8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, ma m); Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ileu-1 Ileu- 1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz) Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 (3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1Hz), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85, (NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation), d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=7.2 Hz); 5-MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m), 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m); 13C NMR (125 MHz TFA/DMF): amino acid unit, δ (carbon position); Val-1 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 12.68 (4); Phe 171.31 (1), 56-27 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172.94 (1), 58.27 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.35 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4), 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5); 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7); IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1464 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85); UV (MeOH): λmax 204 (89,630) nm.
4. The pharmaceutical composition of claim 3, wherein the compound Kahalalide F compound further has the folowing non-streospecific following non-stereospecific structure
Figure USRE039496-20070227-C00005
5. A method of treating fungal infections in mammals comprising administering to a patient in need of such treatment, an amount of the substantially puxe compound pure Kahalalide F compound or a pharmaceutically acceptable salt thereof, sufficient to slow or stop the growth of the fungal infection; said compound having a molecula molecular formula of C75H124N14O16, and consisting of five valines, two isoleucines, two theonines threonines, ornithine, dehydroaminobutiric dehydroaminobutyric acid, proline, phenylalanie phenylalanine and 5-methylhexanoic acid; said compound further exhibiting the folowing following physical and chemical properties:
[α]D-8° (c 4.32, MEOH); 1H NMR (500 MHz, TFA/DMF); amino acid unit, δ (carbon position, mult, J): Val-1 4.16 (2, t, J=9.0 Hz), 7.11 (NH on 2, d, J=8,9 8.9 Hz), 1.77 (3, m), 0.95 (4, m), 0.95 (5, ma m); Dhb 9.20 (NH on 2, s), 6.48 (3, q, J=6.9 Hz), 1.43 (4, d, J=6.6 Hz); Phe 4.68 (2, q, J=6.6 Hz), 8.62 (NH on 2, d, J=6.6 Hz), 3.23 (3, dd, J=13.7, 7.2 Hz), 3.00 (3, dd, J=13.7, 9.0 Hz), 7.32 (5, d, J=7.2 Hz), 7.28 (6, t, J=7.5 Hz), 7.21 (7, t, J=7.2 Hz); Val-2 4.36 (2, m), 7.82 (NH on 2, d, J=6.6 Hz), 2.12 (3, m), 0.85 (4, m), 0.77 (5, d, J=6.6 Hz); Ilue-1 Ileu- 1 4.53 (2, m), 8.38 (NH on 2, d, J=9.6 Hz), 1.98 (3, m), 0.92 (4, d, J=6.6 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, t, J=7.2 Hz); Thr-1 4.63 (2, t, J=9.3 Hz), 8.12 (NH on 2, d, J=5.7), 5.07 (3, dq, J=9.6, 6.0 Hz), 1.18 (4, d, J=6.3 Hz); Ileu-2 4.52 (2, m), 7.72 (NH on 2, d, J=8.4 Hz), 1.88 (3, m), 0.88 (4, d, J=6.3 Hz), 1.40 (5, m), 1.13 (5, m), 0.88 (6, d t, J=7.2 Hz) Orn 4.48 (2, m), 7.92 (NH on 2, d, J=7.8 Hz), 1.76 (3, m), 1.83 (4, m), 3.10 (5, p, J=5.1 Hz); Pro 4.42 (2, m), 2.12 (3, m), 1.97 (3, m), 2.02 (4, m), 1.88 (4, m), 3.75 (5, m), 3.68 (5, m); Val-3 4.41 (2, m), 7.90 (NH on 2, d, J=7.2 Hz), 2.12 (3, m), 0.95 (4, m), 0.85 (5, m); Val-4 4.34 (2, m), 7.68 (NH on 2, d, J=8.1 Hz), 2.17 (3, m), 0.95 (4, m), 0.90 (5, m); Thr-2 4.46 (2, m), 7.77 (NH on 2, d, J=8.1), 4.21 (3, dq, J=6.3, 3.6 Hz), 1.12 (4, d, J=6.6 Hz); Val-5 4.32 (2, m), 7.85, (NH on 2, d, J=8.1 Hz), 7.82 (NH on (second conformation), d, J=8.1 Hz), 2.14 (3, m), 0.95 (4, m), 0.90 (5, m); 5MeHex 2.26 (2, m), 1.60 (3, m), 1.20 (4, m), 1.55 (5, m), 0.87 (6, d, J=7.2 Hz), 0.87 (7, d, J=7.2 Hz); 5MeHex 2.29 (2, m), 1.65 (3, m), 1.40 (3, m) 1.13 (4, m), 1.35 (5, m), 0.90 (6, m), 0.90 (7, m); 13C NMR (125 MHz, TFA/DMF): amino acid unit, 6 (carbon position); Val-1 170.40 (1), 60.31 (2), 30.75 (3), 19.58 (4), 18.76 (5); Dhb 164.54 (1), 130.30 (2), 131.26 (3), 12.68 (4); Phe 171.31 (1), 56-27 56.27 (2), 36.79 (3), 138.23 (4), 129.86 (5), 128.77 (6), 126.98 (7); Val-2 172.94 (1), 58.27 (2), 32.38 (3), 18.92 (4), 17.60 (5); Ileu-1 171.87 (1), 57.48 (2), 38.78 (3), 14.56 (4), 26.78 (5), 11.67 ( 6 ); Thr-1 169.68 (1), 57.37 (2), 71.05 (3), 17.34 (4); Ileu-2 171.92 (1), 57.29 (2), 38.01 (3), 14.78 (4), 26.55 (5), 11.63 (6); Orn 172.01 (1), 52.87 (2), 29.63 (3), 24.39 (4), 40.05 (5); Pro 172.35 172.55 (1), 60.23 (2), 29.58 (3), 25.38 (4), 48.03 (5); Val-3 171.28 (1), 57.57 (2), 30.54 (3), 19.61 (4), 18.80 (5); Val-4 171.83 (1), 59.10 (2), 31.26 (3), 19.45 (4), 18.08 (5); Thr-2 170.97 (1), 58.89 (2), 67.36 (3), 19.66 (4); Val-5 172.67 (1), 59.64 (2), 30.66 (3), 19.61 (4), 18.43 (5); 5-MeHex 173.83 (1), 36.28 (2), 23.99 (3), 38.96 (4), 28.10 (5), 22.54 (6), 22.50 (7); 5-MeHex (second conformation) 174.08 (1), 33.86 (2), 32.84 (3), 29.75 (4), 34.54 (5), 19.51 (6), 11.20 (7); IR neat (NaCl): 3287 (s, br), 2964 (s, br), 1646 (s), 1528 (s), 1464 (s), 1388 (m), 1228 (m), cm−1; mass spectrum HRFAB m/z (fragment, %) 1477.9408 (M++1, 85); UV (MeOH): λmax 204 (89,630) nm.
6. The method of treatment of claim 5, wherein compound Kahalalide F has the following non-stereospecific structure:
Figure USRE039496-20070227-C00006
7. The method of claim 5, wherein the fungal infection is caused by Aspergillus oryzae.
8. The method of claim 5, wherein the fungal infection is caused by Penicillium notatum.
9. The method of claim 5, wherein the fungal infection is caused by Trichophyton mentagrophy.
10. The method of claim 5, wherein the fungal infection is caused by Candida albicans.
US10/642,006 1993-02-03 2003-08-14 Kahalalide F and compositions and uses thereof Expired - Lifetime USRE39496E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/642,006 USRE39496E1 (en) 1993-02-03 2003-08-14 Kahalalide F and compositions and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939302046A GB9302046D0 (en) 1993-02-03 1993-02-03 Antiumoral compound-v
US08/192,569 US6274551B1 (en) 1994-02-03 1994-02-03 Cytotoxic and antiviral compound
US10/642,006 USRE39496E1 (en) 1993-02-03 2003-08-14 Kahalalide F and compositions and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/192,569 Reissue US6274551B1 (en) 1993-02-03 1994-02-03 Cytotoxic and antiviral compound

Publications (1)

Publication Number Publication Date
USRE39496E1 true USRE39496E1 (en) 2007-02-27

Family

ID=22710214

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/192,569 Ceased US6274551B1 (en) 1993-02-03 1994-02-03 Cytotoxic and antiviral compound
US08/935,073 Expired - Lifetime US6011010A (en) 1994-02-03 1997-09-25 Cytotoxic and antiviral compound
US10/642,006 Expired - Lifetime USRE39496E1 (en) 1993-02-03 2003-08-14 Kahalalide F and compositions and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/192,569 Ceased US6274551B1 (en) 1993-02-03 1994-02-03 Cytotoxic and antiviral compound
US08/935,073 Expired - Lifetime US6011010A (en) 1994-02-03 1997-09-25 Cytotoxic and antiviral compound

Country Status (1)

Country Link
US (3) US6274551B1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214755A1 (en) * 2000-02-09 2004-10-28 Fernando Albericio Kahalalide f and related compounds
US20070117743A1 (en) * 2003-09-09 2007-05-24 Palomera Fernando A New antitumoral compounds
US20080090757A1 (en) * 2003-02-26 2008-04-17 Pharma Mar, S.A.U. Kahalalide Compositions for the Treatment of Psoriasis
US7683028B2 (en) 2003-02-26 2010-03-23 Pharma Mar, S.A.U. Kahalalide compositions
US20100226919A1 (en) * 2007-10-19 2010-09-09 Pharma Mar, S.A. Antitumoral Treatments
US20100323021A1 (en) * 2008-01-30 2010-12-23 Pharma Mar, S.A. Antitumoral treatments
US20110015135A1 (en) * 2008-03-07 2011-01-20 Pharma Mar S.A. Antitumoral Treatments
US10538535B2 (en) 2017-04-27 2020-01-21 Pharma Mar, S.A. Antitumoral compounds

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0114912A (en) * 2000-10-31 2003-10-14 Pharma Mar Sa Kahalalide f
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2004035613A2 (en) * 2002-10-18 2004-04-29 Pharma Mar, S.A.U. 4-methylhexanoic kahalaide f compound
US20040248877A1 (en) * 2003-04-30 2004-12-09 Sandeep Gupta Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
US7457885B2 (en) * 2005-02-10 2008-11-25 Asoka Usa Corporation Powerline communication system and method using coupler design for additional users
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035613A2 (en) * 2002-10-18 2004-04-29 Pharma Mar, S.A.U. 4-methylhexanoic kahalaide f compound
US20040214755A1 (en) * 2000-02-09 2004-10-28 Fernando Albericio Kahalalide f and related compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214755A1 (en) * 2000-02-09 2004-10-28 Fernando Albericio Kahalalide f and related compounds
WO2004035613A2 (en) * 2002-10-18 2004-04-29 Pharma Mar, S.A.U. 4-methylhexanoic kahalaide f compound

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Goetz et al, Tetrahedron, 55 (1999), pp. 7729-7746. *
Hamann et al, J. Org. Chem. (1996), 61, 6594-6600. *
Hamann et al., J. Am. Chem. Soc., 115, pp. 5825-5826, Jul. 1, 1993.
Merch Manual, 11<SUP>th </SUP>ed., pp. 456-459, 761-763, and 1368-1371; published 1969.
UMI Dissertation Services, "Biologically Active Constituents of Some Marine Invertebrates," Hamann, Mark Todd, Ph.D., University of Hawaii (1992), published Oct. 1993.

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214755A1 (en) * 2000-02-09 2004-10-28 Fernando Albericio Kahalalide f and related compounds
US7482429B2 (en) * 2000-02-09 2009-01-27 Pharma Mar, S.A. Kahalalide F and related compounds
US20080090757A1 (en) * 2003-02-26 2008-04-17 Pharma Mar, S.A.U. Kahalalide Compositions for the Treatment of Psoriasis
US7683028B2 (en) 2003-02-26 2010-03-23 Pharma Mar, S.A.U. Kahalalide compositions
US20070117743A1 (en) * 2003-09-09 2007-05-24 Palomera Fernando A New antitumoral compounds
US20100226919A1 (en) * 2007-10-19 2010-09-09 Pharma Mar, S.A. Antitumoral Treatments
US20100323021A1 (en) * 2008-01-30 2010-12-23 Pharma Mar, S.A. Antitumoral treatments
US20110015135A1 (en) * 2008-03-07 2011-01-20 Pharma Mar S.A. Antitumoral Treatments
US10538535B2 (en) 2017-04-27 2020-01-21 Pharma Mar, S.A. Antitumoral compounds
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
US11339180B2 (en) 2017-04-27 2022-05-24 Pharma Mar, S.A. Antitumoral compounds
US11713325B2 (en) 2017-04-27 2023-08-01 Pharma Mar, S.A. Antitumoral compounds
US12384800B2 (en) 2017-04-27 2025-08-12 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
US6274551B1 (en) 2001-08-14
US6011010A (en) 2000-01-04

Similar Documents

Publication Publication Date Title
USRE39496E1 (en) Kahalalide F and compositions and uses thereof
KR100248033B1 (en) Cytokine restraining agents
JP2919965B2 (en) Dehydrodidemnin B
CA1270596A (en) Peptide derivatives having a nitrogenous polycyclic structure and process for their preparation
US6239104B1 (en) Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
EP0610078B1 (en) Cytotoxic and antiviral compound
US8435939B2 (en) Polypeptide anti-HIV agent containing the same
JP3178835B2 (en) Novel polypeptide and anti-HIV agent using the same
HUT73674A (en) Biologically active vasopressin analogues
EP1309613B1 (en) Pharmaceutical composition comprising an analgesic peptide
HU211251A9 (en) Polypeptides with affinity to lipopolysaccharides and their uses
DE68905552T2 (en) IMMUNOSTIMULATING PEPTIDES, THEIR PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US20250032573A1 (en) Immunity-enhancing peptide analogs and uses thereof
EP0378432B1 (en) Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation
RU1124544C (en) Heptapeptide possessing properties of psychostimulator of prolonged action with immunotropic activity
DE69030293T2 (en) New peptides, their intermediates, processes for their preparation, antiallergic agents, vasodilators and immunoregulators
IE903958A1 (en) Reduced irreversible bombesin antagonists
EP0428700B1 (en) Irreversible bombesin antagonists
JPH0672152B2 (en) Thymosin α1-fragment and immunomodulator containing the compound
US3948876A (en) Process for the purification of synthetic calcitonins
WO1997039025A1 (en) A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp.
US6589937B1 (en) Peptides and nootropic agent
AU678329C (en) Cytokine restraining agents
CA2128552A1 (en) Derivatives of 6,7-dihydroxy-4-thiaheptanoic acid and their use
US20040033940A1 (en) Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12